

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

NCT06803888

Status	RECRUITING
Phase	Phase 4
Sponsor	Ali Aminian
Enrollment	125 participants

Key Eligibility Criteria

Inclusion (11)

- Entry into the study would require that the patient:
 - Is a candidate for general anesthesia
 - Is eligible for bariatric surgery (RYGB or SG) based on ASMBS/IFSO 2022 guidelines
 - Is e18 and d70 years old (both inclusive)
 - has a BMI e35 and d65 kg/m2 (both inclusive)
- ... and 6 more (see full listing online)

Exclusion (37)

- Significant cardiac or atherosclerotic disease (planned to undergo cardiac, coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
 - Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V
 - Classified as New York Heart Association Class IV
 - Left ventricular ejection fraction $\leq 25\%$ at the time of screening (if already known)
 - Myocardial infarction, unstable angina, stroke, transient ischemic attack, heart surgery, coronary stent placement in the past 6 months
- ... and 32 more (see full listing online)

Locations (1 total)

The Cleveland Clinic, Cleveland, Ohio, United States

<https://clinicaltrials.gov/study/NCT06803888>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.